Contact Information

Primary Contact

Simona Colantonio


1050 Boyles Street
Frederick, MD 21702


The Antibody Characterization Laboratory (ACL) is the laboratory responsible for the development of well-characterized monoclonal antibody reagents. The NCI’s Office of Cancer Clinical Proteomics Research funds ACL as a resource to the entire cancer research community. ACL produces monoclonal antibodies to putative cancer targets selected by an Antibody Scientific Committee, and each antibody is characterized using optimized Standard Operating Procedures (SOPs). Approximately once a year there is a reagent target request open to the extramural research community. ACL is operated by Leidos Biomedical Research Inc. on behalf of NCI as part of the Frederick National Laboratory.

Antibody Characterization

The ACL engages in the characterization of monoclonal antibodies using an SOP-driven set of standard assays that provide a baseline understanding of the performance of antibodies in a variety of different assays including SDS-PAGE, Western blot, ELISA, Immunohistochemistry, Immuno Mass Spectroscopy and Surface Plasmon Resonance. Antibody characterization data is publicly available at Antibody Data Portal help accelerate cancer research.

Monoclonal Antibodies and Cell Lines

Monoclonal antibodies and hybridomas are available at the Developmental Studies Hybridoma Bank for research use only and to commercial entities through non-exclusive licensing agreements for more information contact

Immunoassay Development

ACL staff have expertise in the development of immunoassay and are available for consultation. Expertise includes Design, development, and deployment of the FDA-approved assay; cGMP design of reagents and documentation; Clinical laboratory operation and management; Antibody selection and pairing.

Established Technologies

  • Western blot techniques using homologous antigen, and antibody – traditional Western Blot (WB), automated Western Blot (Wes) and Single Cell Western Blot (SC-Wes)
  • Antibody-specific activity calculated from indirect ELISA titration for binding an antibody concentration assays
  • Affinity measurements by Surface Plasmon Reference (SPR) and Biolayer Interferometry (BLI)
  • Immuno-Fluorescence (IF)
  • Immuno-precipitation (IP) with WB or mass spectrometry detection
  • Immuno-MRM for peptide detection and quantification
  • Immuno-histochemistry (IHC)
  • NCI60 Reverse Phase Protein Array (RPPA)
  • PAGE for purity
  • Isotype analysis
  • Open resource characterization data via the Antibodies Data Portal


Antibody-specific activityELISAIHCImmuno Mass SpectroscopyImmunohistochemistryIsotype analysisProtein ArraySDS-PAGESurface Plasmon ResonanceTissue array (reverse phase) with NCI 60Western blotantibodyantibody characterizationantibody concentration assayscustom antibodiesProteins and Proteomicsimmunoassaysindirect ELISA titrationmonoclonal antibodiesnci-ncr